



This is a repository copy of *The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/108569/>

Version: Supplemental Material

Article:

Stevenson, M.D. orcid.org/0000-0002-3099-9877, Wailoo, A.J. orcid.org/0000-0002-9324-1617, Tosh, J.C. et al. (8 more authors) (2017) The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate. *Journal of Rheumatology*, 44 (7). pp. 973-980. ISSN 0315-162X

<https://doi.org/10.3899/jrheum.160941>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 2: The estimated deterministic ICERs for bDMARD strategies compared with a cDMARD strategy.

	Base case analyses		Supplementary analyses	
	Base case	Assuming HAQ progression in trajectories 3 and 4 until year 40	Base case	Assuming HAQ progression in trajectories 3 and 4
Severe RA	£41,600 (£40,800)	£40,800 (£40,100)	£25,300 (£24,800)	£23,900 (£23,500)
	All patients		Those patients with greatest HAQ progression	
	Base case	Assuming HAQ progression in trajectories 3 and 4 until year 40	Base case	Assuming HAQ progression in trajectories 3 and 4
Moderate-to-severe RA	£51,100 (£49,800)	£49,100 (£48,900)	£28,500 (£28,100)	£25,700 (£25,400)

All numbers rounded to the nearest £100